Medical Research Journal最新文献_第4页

New method of treating type 1 diabetes — closed-loop system 治疗1型糖尿病的新方法——闭环系统

Medical Research Journal Pub Date : 2023-09-18 DOI: 10.5603/mrj.97386

Karolina Matuszewska, Adrian Bystroń

引用次数: 0

Breast apocrine carcinoma: a case report and review of literature 乳腺大汗腺癌1例报告及文献复习

Medical Research Journal Pub Date : 2023-09-14 DOI: 10.5603/mrj.96297

Bindu Abraham, Philip Idaewor, Ali Salih, Wayne Chicken, Mohamed Elamass, Jessica English, Vanessa Kendle, Denise Bonner, Christiana Aryee, Helen Merron, Elin Edwards, Noreen Rasheed, Abdalla Saad Abdalla Al-Zawi

引用次数: 0

Artificial oxygen carriers in emergency medicine 急救医学中的人工氧载体

Medical Research Journal Pub Date : 2023-09-13 DOI: 10.5603/mrj.96727

Jakub Kobiałka, Ugo Giordano

引用次数: 0

Efficacy of double vs. standard empagliflozin dose for METabolic syndromE tReatment (DEMETER — SIRIO 11) study. Rationale and protocol of the study 双剂量与标准剂量恩格列净治疗代谢综合征的疗效(DEMETER - SIRIO 11)研究。研究的基本原理和方案

Medical Research Journal Pub Date : 2023-09-08 DOI: 10.5603/mrj.97187

J. Kubica, A. Kubica, Z. Grąbczewska, Paweł Stróżecki, Piotr Adamski, A. Brymora, Rafał Donderski, T. Fabiszak, M. Flisiński, Robert Gajda, Beata Januszko-Giergielewicz, Przemysław Magielski, P. Michalski, M. Kasprzak, A. Kosobucka-Ozdoba, E. Laskowska, G. Casu, E. Navarese, Piotr Niezgoda, M. Ostrowska, Łukasz Pietrzykowski, Grzegorz Skonieczny, B. Sulikowska, Łukasz Szarpak, P. Szymański, Julia M Umińska, Paweł Zalewski

{"title":"Efficacy of double vs. standard empagliflozin dose for METabolic syndromE tReatment (DEMETER — SIRIO 11) study. Rationale and protocol of the study","authors":"J. Kubica, A. Kubica, Z. Grąbczewska, Paweł Stróżecki, Piotr Adamski, A. Brymora, Rafał Donderski, T. Fabiszak, M. Flisiński, Robert Gajda, Beata Januszko-Giergielewicz, Przemysław Magielski, P. Michalski, M. Kasprzak, A. Kosobucka-Ozdoba, E. Laskowska, G. Casu, E. Navarese, Piotr Niezgoda, M. Ostrowska, Łukasz Pietrzykowski, Grzegorz Skonieczny, B. Sulikowska, Łukasz Szarpak, P. Szymański, Julia M Umińska, Paweł Zalewski","doi":"10.5603/mrj.97187","DOIUrl":"https://doi.org/10.5603/mrj.97187","url":null,"abstract":"Complex metabolic disorders associated with obesity and diabetes pose a serious therapeutic challenge. The DEMETER-SIRIO 11 study is a phase III, multicenter, randomized, open-label, investigator-initiated clinical trial with a 6-month follow-up aimed at performing a comparative evaluation of the effect of two empagliflozin doses (10 mg vs. 20 mg) on selected metabolic parameters in patients with metabolic syndrome. The primary hypothesis of the study is that a higher dose of empagliflozin will result in a significant reduction of BMI and HbA1c in patients with obesity and MS receiving empagliflozin 20 mg as compared to 10 mg. Sample size and power calculation were based on a superiority assumption for the primary efficacy endpoint (the difference in decrease of body weight by > 1.5 kg and HbA1c by > 0.4%) for the higher vs. standard dose arm at 6-months of follow-up. Therefore, a sample size of 79 patients per arm is required to provide 80% power to detect a higher decrease in BMI, and 85 patients per arm is required to provide 80% power to detect a higher decrease in HbA1c in the 20 mg versus 10 mg arm with a type I error rate of 0.05. Summing up, enrollment of a total of 200 patients (100 in each arm) is planned to compensate for the potential drop-out rate from the study of up to 15%. Prespecified subanalyses will be performed according to: 1","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75033323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of combined action of doxorubicin and calcifediol on MCF-7 breast cancer cells 阿霉素和钙化二醇联合作用对MCF-7乳腺癌细胞的影响

Medical Research Journal Pub Date : 2023-08-22 DOI: 10.5603/mrj.96387

Oliwia Abramczyk, Sylwia Stawieraj, Agnieszka Mlicka, Wioletta Zielińska, Paweł Niewiadomski, Marta Hałas-Wiśniewska, M. Izdebska

{"title":"Effect of combined action of doxorubicin and calcifediol on MCF-7 breast cancer cells","authors":"Oliwia Abramczyk, Sylwia Stawieraj, Agnieszka Mlicka, Wioletta Zielińska, Paweł Niewiadomski, Marta Hałas-Wiśniewska, M. Izdebska","doi":"10.5603/mrj.96387","DOIUrl":"https://doi.org/10.5603/mrj.96387","url":null,"abstract":"Introduction : Breast cancer is one of the most common cancers in women. Current recommendations for combination therapy in patients with breast cancer are still being developed and new therapies with greater success are sought. A relatively new approach is the administration of cytostatics in combination with vitamins. Hence, the study aimed to clarify whether the combination of calcifediol [25(OH)D3] with doxorubicin affects the response of the MCF-7 breast cancer cell line to the cytostatic. Material and methods : In the MCF-7 cell line, the authors assessed cytotoxicity using the MTT assay, analysed the cell cycle and cell death mechanism using flow cytometry, and examined the structure of the cytoskeleton and cell morphology. Results : The results showed that doxorubicin in combination with calcifediol in a 1:1 ratio showed a synergistic effect resulting in a dose-dependent decrease in cell survival. Further studies have shown that this is due to the pro-apoptotic and necrotic effects of the combination of these compounds. There were also changes in the organization of the cytoskeleton and cell morphology. In addition, features of entosis were noted in MCF-7 cells. Conclusion : The synergistic effect of doxorubicin and calcifediol significantly reduced the viability of MCF-7 breast cancer cells. Inducing the desired effect by lowering the cytostatic dose is of great clinical importance, taking into account the cardiotoxicity of doxorubicin. Another very interesting aspect is the entosis process induced in the present research, which may have a dual nature.","PeriodicalId":18485,"journal":{"name":"Medical Research Journal","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83906511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression of KIM-1, VEGF and bFGF in the transplanted kidney as predictive factors of kidney allograft function 移植肾中KIM-1、VEGF和bFGF的表达作为异体肾移植功能的预测因素

Medical Research Journal Pub Date : 2023-08-22 DOI: 10.5603/mrj.95927

T. Sulikowski, Agnieszka Orłowska-Szafrańska, J. Pawlus, Jarosław Lichota, K. Ciechanowski, M. Marchelek-Myśliwiec, A. Brodkiewicz, K. Safranow, L. Domański, A. Pawlik

引用次数: 0

Use of the systemic immune-inflammation index to predict the severity of pneumonia in the emergency department 应用全身免疫-炎症指数预测急诊科肺炎严重程度

Medical Research Journal Pub Date : 2023-08-21 DOI: 10.5603/mrj.96312

Fatma Tortum, E. Tekin, Emine Ozdal

引用次数: 0

High-flow oxygen therapy — its application in COVID-19-related respiratory failure and beyond 高流量氧疗在covid -19相关呼吸衰竭及其他疾病中的应用

Medical Research Journal Pub Date : 2023-08-01 DOI: 10.5603/mrj.a2023.0037

Martyna Wyszyńska-Gołaszewska, Mateusz Łukaszyk, W. Naumnik

引用次数: 0

Interpersonal communication between medical rescue service employees and patients as perceived by patients 患者感知的医疗救护人员与患者之间的人际沟通

Medical Research Journal Pub Date : 2023-07-28 DOI: 10.5603/mrj.a2023.0036

Justyna M. Graniczna, Anna Burak